Topical administration of coumarin derivatives alleviates skin inflammatory symptoms in atopic dermatitis model

IF 7.5 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Biomedicine & Pharmacotherapy Pub Date : 2025-03-28 DOI:10.1016/j.biopha.2025.118004
Goeun Han , Bon-Hee Gu , Sun Young Park , Da Som Park , Su Mi Hwang , Woonhak Ji , Seon Beom Kim , Myunghoo Kim
{"title":"Topical administration of coumarin derivatives alleviates skin inflammatory symptoms in atopic dermatitis model","authors":"Goeun Han ,&nbsp;Bon-Hee Gu ,&nbsp;Sun Young Park ,&nbsp;Da Som Park ,&nbsp;Su Mi Hwang ,&nbsp;Woonhak Ji ,&nbsp;Seon Beom Kim ,&nbsp;Myunghoo Kim","doi":"10.1016/j.biopha.2025.118004","DOIUrl":null,"url":null,"abstract":"<div><div>The prevalence of atopic dermatitis (AD), a chronic inflammatory skin condition, is increasing. Coumarin derivatives, plant secondary metabolites, possess anti-inflammatory properties, but their specific role in AD treatment remain unclear. This study investigated the therapeutic potential of 7-geranyloxycoumarin (C#6), a selective coumarin derivative, in alleviating AD-like symptoms through multifaceted mechanisms. Among various coumarin derivatives tested, C#6 demonstrated remarkable efficacy in both <em>in vitro</em> and <em>in vivo</em> models. Notably, C#6 significantly suppressed interleukin-8 and thymic stromal lymphopoietin production in stimulated HaCaT cells. Experiments on an MC903-induced mouse model of AD revealed that topical administration of C#6 for 10 days led to a significant reduction in ear and epidermal thickness. Flow cytometry analysis showed a significant decrease in CD45 + leukocytes, eosinophils, and Th2 cells in C#6-treated AD mice. Importantly, 16S rRNA sequencing indicated that C#6 restored the disrupted skin microbiome by increasing the abundance of beneficial <em>Lactobacillus</em> and reducing pathogenic bacteria such as <em>Enterobacteriaceae</em>, <em>Corynebacteriaceae</em>, and <em>Corynebacterium</em>, contributing to maintaining skin microbiome balance. Molecular docking studies revealed high binding affinities of C#6 to key regulators, including NOD1, TLR2, PAR2, and TLR3, suggesting a role in modulating critical inflammatory pathways. Additionally, co-culture experiments revealed that C#6 treatment of TNF-α and IFN-γ-stimulated HaCaT cells suppressed inflammatory cytokines expression by THP-1 cells. Collectively, these findings demonstrate that C#6 exerts its anti-atopic effects by suppressing Th2-driven inflammation, reducing eosinophilic infiltration, modulating immune-epidermal crosstalk, and maintaining skin microbiome homeostasis, highlighting its potential as a promising therapeutic agent for AD management.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"186 ","pages":"Article 118004"},"PeriodicalIF":7.5000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine & Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0753332225001982","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

The prevalence of atopic dermatitis (AD), a chronic inflammatory skin condition, is increasing. Coumarin derivatives, plant secondary metabolites, possess anti-inflammatory properties, but their specific role in AD treatment remain unclear. This study investigated the therapeutic potential of 7-geranyloxycoumarin (C#6), a selective coumarin derivative, in alleviating AD-like symptoms through multifaceted mechanisms. Among various coumarin derivatives tested, C#6 demonstrated remarkable efficacy in both in vitro and in vivo models. Notably, C#6 significantly suppressed interleukin-8 and thymic stromal lymphopoietin production in stimulated HaCaT cells. Experiments on an MC903-induced mouse model of AD revealed that topical administration of C#6 for 10 days led to a significant reduction in ear and epidermal thickness. Flow cytometry analysis showed a significant decrease in CD45 + leukocytes, eosinophils, and Th2 cells in C#6-treated AD mice. Importantly, 16S rRNA sequencing indicated that C#6 restored the disrupted skin microbiome by increasing the abundance of beneficial Lactobacillus and reducing pathogenic bacteria such as Enterobacteriaceae, Corynebacteriaceae, and Corynebacterium, contributing to maintaining skin microbiome balance. Molecular docking studies revealed high binding affinities of C#6 to key regulators, including NOD1, TLR2, PAR2, and TLR3, suggesting a role in modulating critical inflammatory pathways. Additionally, co-culture experiments revealed that C#6 treatment of TNF-α and IFN-γ-stimulated HaCaT cells suppressed inflammatory cytokines expression by THP-1 cells. Collectively, these findings demonstrate that C#6 exerts its anti-atopic effects by suppressing Th2-driven inflammation, reducing eosinophilic infiltration, modulating immune-epidermal crosstalk, and maintaining skin microbiome homeostasis, highlighting its potential as a promising therapeutic agent for AD management.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
局部施用香豆素衍生物可减轻特应性皮炎模型的皮肤炎症症状
特应性皮炎(AD)是一种慢性炎症性皮肤疾病,其患病率正在上升。香豆素衍生物是植物次生代谢产物,具有抗炎特性,但其在阿尔茨海默病治疗中的具体作用尚不清楚。本研究探讨了7-香豆素氧基香豆素(c# 6),一种选择性香豆素衍生物,通过多方面机制缓解ad样症状的治疗潜力。在测试的各种香豆素衍生物中,c# 6在体外和体内模型中都表现出显著的功效。值得注意的是,c# 6显著抑制了受刺激的HaCaT细胞中白细胞介素-8和胸腺基质淋巴生成素的产生。mc903诱导的AD小鼠模型实验表明,局部给予c# 6 10天可显著减少耳和表皮厚度。流式细胞术分析显示c# 6治疗的AD小鼠CD45 + 白细胞、嗜酸性粒细胞和Th2细胞显著减少。重要的是,16S rRNA测序表明,c# 6通过增加有益乳杆菌的丰度,减少肠杆菌科、棒状杆菌科和棒状杆菌等致病菌,恢复了被破坏的皮肤微生物群,有助于维持皮肤微生物群平衡。分子对接研究显示c# 6与关键调控因子(包括NOD1、TLR2、PAR2和TLR3)具有高结合亲和力,提示其在调节关键炎症通路中发挥作用。此外,共培养实验显示,c# 6处理TNF-α和IFN-γ刺激的HaCaT细胞抑制THP-1细胞的炎症因子表达。总之,这些发现表明c# 6通过抑制th2驱动的炎症、减少嗜酸性粒细胞浸润、调节免疫-表皮串扰和维持皮肤微生物组稳态来发挥其抗特应性作用,突出了其作为AD治疗药物的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.90
自引率
2.70%
发文量
1621
审稿时长
48 days
期刊介绍: Biomedicine & Pharmacotherapy stands as a multidisciplinary journal, presenting a spectrum of original research reports, reviews, and communications in the realms of clinical and basic medicine, as well as pharmacology. The journal spans various fields, including Cancer, Nutriceutics, Neurodegenerative, Cardiac, and Infectious Diseases.
期刊最新文献
Identifying novel biomarkers for systemic lupus erythematosus associated with macrophage activation syndrome Hedera helix-derived α−hederin (IVL-11) demonstrates both ex vivo and in vivo flukicidal activities against Fasciola hepatica Platelet extracellular vesicles drive monocyte differentiation into inflammatory foam cells in peripheral arterial disease Exosome-mediated antiviral testing system and identification of Punicalagins and Anthocyanidins as promising antiviral agents against SARS-CoV-2 Manipulation of tumor microenvironment by induction of immunogenic cell death and immune check point inhibitors for enhancing the efficacy of cancer treatments
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1